IL36A/IL1F6 Protein (AA 6-158)

Catalog No. ABIN2666739

Recombinant IL36A/IL1F6 protein expressed in Escherichia coli (E. coli).

Quick Overview for IL36A/IL1F6 Protein (AA 6-158) (ABIN2666739)

Target: IL36A/IL1F6 (IL1F6) (Interleukin 1 Family, Member 6 (IL1F6))

Protein Type: Recombinant

Biological Activity: Active

Origin: Human

Source: Escherichia coli (E. coli)

Application: Flow Cytometry (FACS), Intracellular Flow Cytometry (ICFC)

Purity: > 97 % , as determined by Coomassie stained SDS-PAGE.

Product Details

Protein Characteristics: AA 6-158

Sterility: 0.22 μm filtered

Endotoxin Level:

Less than 0.01 ng per μg cytokine as determined by the LAL method.

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Comment:

Biological activity: The ED50 is 20 - 50 ng/ml, corresponding to a specific activity 2 - 5 x 104 units/mg, as determined by a dose-dependent stimulation of IL-8 secretion in human preadipocytes.

Restrictions: For Research Use only

Handling

Format: Liquid

Reconstitution: For maximum results, quick spin vial prior to opening. Stock solutions should be prepared at no less than 10 μg/mL in sterile buffer (PBS, HPBS, DPBS, and EBSS) containing carrier protein such as 1 % BSA or HSA.

Buffer: 0.22 μm filtered protein solution is in 20 mM Hepes pH 7.2, 150 mM NaCl, 10 mM TCEP.

Handling Advice: Avoid repeated freeze/thaw cycles.

Storage: -20 °C

Storage Comment: Unopened vial can be stored between 2°C and 8°C for one week, at -20°C for three months, or at -70°C for 6 months.

Target Details

Target: IL36A/IL1F6 (IL1F6) (Interleukin 1 Family, Member 6 (IL1F6))

Alternative Name: IL-36 alpha

Background: IL-36α is one of the IL-36 cytokines that are part of the IL-1 family. Like other IL-1 family members, IL-36α requires N-terminal processing to gain full bioactivity, currently, the proteases responsible for processing IL-36α are unknown. IL-36α signals through IL-36R/IL-1RAcP, which results in MAPK, Erk1/2, and JNK activation. IL-36α is implicated in skin homeostasis, and it is overexpressed in psoriatic lesional skin. Transgenic mice overexpressing IL-36α in skin have an inflammatory skin condition showing some characteristics of human psoriasis, including thickened scaly skin, acanthosis, hyperkeratosis, and dermis infiltration. EGF regulates the expression of IL-36α in the skin. IL-36α can also be detected in adipose tissue. IL-36α reduces adipocyte differentiation and also induces inflammatory gene expression in mature adipocytes. In lungs, the expression of IL-36α is increased in response to inflammatory stimuli. Intratracheal instillation of recombinant mouse IL-36α induces CXCL1 and CXCL2 expression and also neutrophil influx in the lungs. IL-36α, IL-36β, and IL-36γ induce in vitro expression of RNA of multiple cytokines (IL-6, IL-12 p40, CXCL1, CCL1, IL-12 p35, IL-1b, IL-19 p19, GM-CSF, CXCL10, TNFα, CCL3, VCAM-1, and ICAM-1) in mouse bone marrow-derived dendritic cells and CD4 T cells obtained from normal mice. IL-36α expression is elevated in chronic kidney disease and in rheumatoid arthritis synovium, and decreased expression correlates with a poor prognosis in hepatocellular carcinoma.

Molecular Weight: The 153 amino acid recombinant protein has a predicted molecular mass of approximately 17 kDa. The DTT-reduced and non-reduced protein migrate at approximately 17 kDa by SDS-PAGE. The predicted N-terminal amino acid is Lys.

Pathways: Cancer Immune Checkpoints